[ad_1]
Celltrion ‘Rekirona’ Corona 19 Antibody Treatment. It began to be supplied to medical institutions nationwide from 17. Celltrion provided
It was estimated that 151 vials were supplied to four medical institutions on the first day of supply of the antibody treatment drug ‘Rekironaju’ for a new Korean coronavirus infection (COVID-19, Corona 19).
The Central Defense Countermeasures Headquarters (Bang Dae-bon) announced that the supply status of 960 mg (regdanbimab) of Celltrion’s Rekkirona juice was identified at 0 o’clock on the 18th.
Rekironaju began to be supplied to medical institutions nationwide from day 17, and among patients confirmed by corona19 of the Ministry of Food and Drug Safety, patients within 7 days from the onset of symptoms, among patients who do not need oxygen therapy, are over 60 years of age or with underlying diseases, accompanied by pneumonia Conditional permission has been obtained for administration to patients.
Daebon Bang explained that the ‘mdesivir’ case, which was imported especially as a treatment for Corona 19, was currently administered to 4,522 patients in 121 hospitals.
In the case of blood system medicine, 38 cases were approved by the Ministry of Food and Pharmaceutical Safety for treatments other than clinical trials.
Meanwhile, in the case of the Corona 19 virus, which began pre-sales through the National Bank of Pathogens Resources on the 8th of this month, so far 832 cases have been anticipated to a total of 208 institutions. Among them, a total of 5 weeks for the UK mutant virus and a total of 5 weeks for the South African mutant virus. A total of 537 nucleic acids were sold.
The recent appearance and spread of a mutant virus is emerging as an important variable that will determine the future corona epidemic19. Pfizer of the USA announced on the 17th (local time) that its corona19 vaccine could reduce the level of antibody protection against the South African mutant virus by approximately two-thirds, which could reduce the preventive effect.
Yang Dong-gyo, head of the Resource Management Division of the Corona 19 Vaccination Response Promotion Team, said: “I know that each manufacturer has started a vaccine development study to respond to the mutant virus.” “We plan to respond to needed areas while continually monitoring the vaccine development process.”
As of day 18, there were a total of 99 confirmed cases of mutant virus in Korea, including 80 mutant infections from the UK, 13 mutant infections from South Africa, and 6 mutant infections from Brazil.
[ad_2]
